Lead Product(s): Pegcetacoplan
Therapeutic Area: Hematology Product Name: APL-2
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Apellis Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
Treatment with pegcetacoplan resulted in a sustained improvement in haemoglobin with a mean increase from baseline of 2.7 g/dL at week 48, which is equal to the 2.7 g/dL increase seen at week 16 with pegcetacoplan-treated patients.